Francois Brisebois
Stock Analyst at Oppenheimer
(1.32)
# 3,321
Out of 4,784 analysts
89
Total ratings
32.95%
Success rate
-10.08%
Average return
Main Sectors:
Stocks Rated by Francois Brisebois
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SNSE Sensei Biotherapeutics | Maintains: Outperform | $3.5 → $4 | $0.51 | +686.94% | 2 | Mar 28, 2025 | |
| ABEO Abeona Therapeutics | Initiates: Outperform | $16 | $4.97 | +221.93% | 1 | Mar 5, 2025 | |
| OVID Ovid Therapeutics | Upgrades: Outperform | $4 | $0.35 | +1,042.86% | 1 | Jan 29, 2025 | |
| TARS Tarsus Pharmaceuticals | Maintains: Outperform | $65 → $72 | $51.74 | +39.16% | 7 | Jan 22, 2025 | |
| MNMD Mind Medicine (MindMed) | Reiterates: Outperform | $20 | $6.19 | +223.10% | 4 | Dec 17, 2024 | |
| TRDA Entrada Therapeutics | Maintains: Outperform | $25 → $28 | $9.56 | +192.89% | 2 | Nov 6, 2024 | |
| AVDL Avadel Pharmaceuticals | Maintains: Outperform | $29 → $30 | $8.01 | +274.53% | 8 | Oct 31, 2024 | |
| PRAX Praxis Precision Medicines | Maintains: Outperform | $143 → $163 | $38.66 | +321.62% | 4 | Oct 31, 2024 | |
| HRMY Harmony Biosciences Holdings | Reiterates: Outperform | $56 → $59 | $33.19 | +77.76% | 5 | Oct 30, 2024 | |
| DYN Dyne Therapeutics | Reiterates: Outperform | $55 | $11.45 | +380.35% | 5 | Sep 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $15 | $6.05 | +147.93% | 2 | Aug 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $6 | $3.82 | +57.07% | 5 | Aug 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $11 | $2.78 | +295.68% | 6 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $14 | $14.59 | -4.04% | 2 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11 → $15 | $2.91 | +415.46% | 4 | Jun 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $25 | $4.61 | +442.30% | 1 | Jun 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $55 → $65 | $24.29 | +167.60% | 5 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $10 | $6.67 | +49.93% | 2 | May 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $5 | $0.80 | +525.00% | 3 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $152 | $6.72 | +2,161.90% | 2 | Aug 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $63 → $36 | $15.95 | +125.71% | 4 | Aug 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $5 → $4 | $2.14 | +86.92% | 3 | Apr 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $100 → $60 | $0.39 | +15,324.16% | 3 | Apr 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $7,200 → $5,400 | $2.90 | +186,106.90% | 2 | Feb 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $8.5 | $3.02 | +181.46% | 1 | Sep 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $17 → $11 | $3.54 | +210.73% | 2 | Aug 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $18 | $1.51 | +1,092.05% | 1 | Jul 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $50 | $2.94 | +1,600.68% | 1 | Oct 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $3,240 | $1.59 | +203,673.58% | 1 | Feb 4, 2020 |
Sensei Biotherapeutics
Mar 28, 2025
Maintains: Outperform
Price Target: $3.5 → $4
Current: $0.51
Upside: +686.94%
Abeona Therapeutics
Mar 5, 2025
Initiates: Outperform
Price Target: $16
Current: $4.97
Upside: +221.93%
Ovid Therapeutics
Jan 29, 2025
Upgrades: Outperform
Price Target: $4
Current: $0.35
Upside: +1,042.86%
Tarsus Pharmaceuticals
Jan 22, 2025
Maintains: Outperform
Price Target: $65 → $72
Current: $51.74
Upside: +39.16%
Mind Medicine (MindMed)
Dec 17, 2024
Reiterates: Outperform
Price Target: $20
Current: $6.19
Upside: +223.10%
Entrada Therapeutics
Nov 6, 2024
Maintains: Outperform
Price Target: $25 → $28
Current: $9.56
Upside: +192.89%
Avadel Pharmaceuticals
Oct 31, 2024
Maintains: Outperform
Price Target: $29 → $30
Current: $8.01
Upside: +274.53%
Praxis Precision Medicines
Oct 31, 2024
Maintains: Outperform
Price Target: $143 → $163
Current: $38.66
Upside: +321.62%
Harmony Biosciences Holdings
Oct 30, 2024
Reiterates: Outperform
Price Target: $56 → $59
Current: $33.19
Upside: +77.76%
Dyne Therapeutics
Sep 3, 2024
Reiterates: Outperform
Price Target: $55
Current: $11.45
Upside: +380.35%
Aug 19, 2024
Reiterates: Outperform
Price Target: $15
Current: $6.05
Upside: +147.93%
Aug 16, 2024
Reiterates: Outperform
Price Target: $6
Current: $3.82
Upside: +57.07%
Aug 15, 2024
Reiterates: Outperform
Price Target: $11
Current: $2.78
Upside: +295.68%
Aug 14, 2024
Reiterates: Outperform
Price Target: $14
Current: $14.59
Upside: -4.04%
Jun 26, 2024
Maintains: Outperform
Price Target: $11 → $15
Current: $2.91
Upside: +415.46%
Jun 25, 2024
Initiates: Outperform
Price Target: $25
Current: $4.61
Upside: +442.30%
Jun 13, 2024
Maintains: Outperform
Price Target: $55 → $65
Current: $24.29
Upside: +167.60%
May 6, 2024
Reiterates: Outperform
Price Target: $10
Current: $6.67
Upside: +49.93%
Apr 1, 2024
Reiterates: Outperform
Price Target: $5
Current: $0.80
Upside: +525.00%
Aug 30, 2023
Reiterates: Outperform
Price Target: $152
Current: $6.72
Upside: +2,161.90%
Aug 17, 2023
Maintains: Outperform
Price Target: $63 → $36
Current: $15.95
Upside: +125.71%
Apr 4, 2023
Maintains: Outperform
Price Target: $5 → $4
Current: $2.14
Upside: +86.92%
Apr 3, 2023
Maintains: Outperform
Price Target: $100 → $60
Current: $0.39
Upside: +15,324.16%
Feb 6, 2023
Maintains: Outperform
Price Target: $7,200 → $5,400
Current: $2.90
Upside: +186,106.90%
Sep 7, 2022
Initiates: Outperform
Price Target: $8.5
Current: $3.02
Upside: +181.46%
Aug 29, 2022
Maintains: Outperform
Price Target: $17 → $11
Current: $3.54
Upside: +210.73%
Jul 18, 2022
Assumes: Outperform
Price Target: $18
Current: $1.51
Upside: +1,092.05%
Oct 29, 2021
Initiates: Outperform
Price Target: $50
Current: $2.94
Upside: +1,600.68%
Feb 4, 2020
Initiates: Buy
Price Target: $3,240
Current: $1.59
Upside: +203,673.58%